Form 4: Neogenomics Director Anthony P. Zook Reports Stock Option Grant

Director Anthony P. Zook reports acquisition of stock options and restricted stock units in Neogenomics.

Summary

• On June 1, 2024, Anthony P. Zook, a director of Neogenomics Inc., reported the acquisition of stock options and restricted stock units.
• Zook acquired 8,672 stock options with an exercise price of $13.71, exercisable from June 1, 2025, and expiring on June 1, 2034.
• Additionally, Zook acquired 12,254 restricted stock units, vesting from June 1, 2025.
• Zook directly owns 8,353 stock options with an exercise price of $14.82, exercisable from August 10, 2024, and expiring on August 10, 2033.
• Zook also directly owns 11,336 restricted stock units, vesting from August 10, 2024.
• The report was filed on June 4, 2024, by Ali Olivo, Attorney-in-Fact.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine stock option and restricted stock unit grants to a director. It doesn't indicate any significant positive or negative events.

Positives

• The acquisition of stock options and restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

NA

Industry Context

This filing is a routine disclosure related to executive compensation and is common in publicly traded companies.

Stakeholder Impact

• The granting of stock options and restricted stock units aligns the director's interests with those of the shareholders.

Key Dates